Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

cel-sci - CVM

CVM

Close Chg Chg %
4.98 0.16 3.21%

Closed Market

5.14

+0.16 (3.21%)

Volume: 40.43K

Last Updated:

Feb 6, 2026, 3:59 PM EDT

Trade Now

Company Overview: cel-sci - CVM

CVM Key Data

Open

$5.09

 Day Range

4.95 - 5.23

52 Week Range

1.98 - 20.40

 Market Cap

$42.13M

Shares Outstanding

8.41M

 Public Float

7.71M

Beta

0.79

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$7.71

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

79.95K

  

CVM Performance

1 Week
 
 -13.79%
 
1 Month
 
 -8.76%
 
3 Months
 
 -28.98%
 
1 Year
 
 -56.01%
 
5 Years
 
 -99.29%
 

CVM Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 1
Full Ratings ➔

About cel-sci - CVM

CEL-SCI Corp. is a clinical-stage biotechnology company, which engages in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS). Multikine is an investigational immunotherapy for the potential treatment of head and neck cancers. LEAPS is categorized into LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza for hospitalized patients and CEL-2000 and CEL-4000, which are vaccine candidates for the treatment of rheumatoid arthritis. The company was founded by Maximilian de Clara on March 22, 1983 and is headquartered in Vienna, VA.

CVM At a Glance

CEL-SCI Corp.
8229 Boone Boulevard
Vienna, Virginia 22182
Phone 1-703-506-9460 Revenue 0.00
Industry Biotechnology Net Income -25,411,055.00
Sector Health Technology Employees N/A
Fiscal Year-end 09 / 2026
View SEC Filings

CVM Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio N/A
Price to Book Ratio 4.621
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -1.708
Enterprise Value to Sales N/A
Total Debt to Enterprise Value 0.263

CVM Efficiency

Revenue/Employee N/A
Income Per Employee N/A
Receivables Turnover N/A
Total Asset Turnover N/A

CVM Liquidity

Current Ratio 2.26
Quick Ratio 2.201
Cash Ratio 2.135

CVM Profitability

Gross Margin N/A
Operating Margin N/A
Pretax Margin N/A
Net Margin N/A
Return on Assets -92.157
Return on Equity -176.318
Return on Total Capital -100.276
Return on Invested Capital -112.56

CVM Capital Structure

Total Debt to Total Equity 58.807
Total Debt to Total Capital 37.031
Total Debt to Total Assets 33.329
Long-Term Debt to Equity 43.511
Long-Term Debt to Total Capital 27.399
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Cel-sci - CVM

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
- - - -
-
Sales Growth
- - - -
-
Cost of Goods Sold (COGS) incl D&A
3.88M 3.96M 3.97M 3.89M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
3.88M 3.96M 3.97M 3.89M
Depreciation
3.83M 3.92M 3.94M 3.86M
Amortization of Intangibles
49.00K 38.00K 32.00K 27.00K
COGS Growth
+678.23% +1.93% +0.27% -2.12%
Gross Income
(3.88M) (3.96M) (3.97M) (3.89M)
Gross Income Growth
-678.23% -1.93% -0.27% +2.12%
Gross Profit Margin
- - - -
-
2022 2023 2024 2025 5-year trend
SG&A Expense
32.18M 27.52M 22.38M 20.92M
Research & Development
25.36M 22.47M 18.16M 15.89M
Other SG&A
6.82M 5.05M 4.22M 5.04M
SGA Growth
-9.85% -14.49% -18.66% -6.52%
Other Operating Expense
- - - -
-
Unusual Expense
- - - (336.00K)
-
EBIT after Unusual Expense
(35.73M) (31.48M) (26.35M) (24.81M)
Non Operating Income/Expense
107.15K (42.81K) 177.68K 47.62K
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
1.08M 675.42K 745.67K 648.94K
Interest Expense Growth
-5.92% -37.52% +10.40% -12.97%
Gross Interest Expense
1.08M 675.42K 745.67K 648.94K
Interest Capitalized
- - - -
-
Pretax Income
(36.70M) (32.19M) (26.92M) (25.41M)
Pretax Income Growth
-0.93% +12.28% +16.38% +5.61%
Pretax Margin
- - - -
-
Income Tax
- - - -
-
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(36.70M) (32.19M) (26.92M) (25.41M)
Minority Interest Expense
- - - -
-
Net Income
(36.70M) (32.19M) (26.92M) (25.41M)
Net Income Growth
-0.93% +12.28% +16.38% +5.61%
Net Margin Growth
- - - -
-
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(36.70M) (32.19M) (26.92M) (25.41M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(36.70M) (32.19M) (26.92M) (25.41M)
EPS (Basic)
-26.1627 -21.8295 -14.9433 -6.2655
EPS (Basic) Growth
+2.48% +16.56% +31.55% +58.07%
Basic Shares Outstanding
1.44M 1.48M 1.80M 4.06M
EPS (Diluted)
-26.1627 -21.8295 -14.9433 -6.2655
EPS (Diluted) Growth
+2.48% +16.56% +31.55% +58.07%
Diluted Shares Outstanding
1.44M 1.48M 1.80M 4.06M
EBITDA
(32.18M) (27.52M) (22.38M) (20.92M)
EBITDA Growth
+9.85% +14.49% +18.66% +6.52%
EBITDA Margin
- - - -
-

Insider Actions for Cel-sci - CVM

Date Name Shares Transaction Value
Apr 2, 2025 Geert R. Kersten Chief Executive Officer; Director 1,240,378 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $0.23 per share 285,286.94
Apr 2, 2025 Patricia B. Prichep Chief Financial Officer 266,230 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $0.23 per share 61,232.90
Apr 2, 2025 Eyal Talor Chief Scientific Officer 135,013 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $0.23 per share 31,052.99

Cel-Sci in the News